UPDATE: Jefferies Starts Gemini Therapeutics Inc. (GMTX) at Buy

March 3, 2021 4:46 AM EST
Get Alerts GMTX Hot Sheet
Price: $9.61 +11.48%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 4 | New: 24
Trade Now! 
Join SI Premium – FREE
(Updated - March 3, 2021 8:25 AM EST)

Jefferies analyst Chris Howerton initiates coverage on Gemini Therapeutics Inc. (NASDAQ: GMTX) with a Buy rating and a price target of $23.00.

The analyst commented, "Gemini is a precision medicine company developing treatments for patients with high-risk genotypes in ophthalmology. Its lead candidate is the first recombinant Complement Factor H (CFH) for late-stage dry AMD (GA) pts with CFH loss-of-function variants (~40%of 1.4M patients), for which there are no currently approved therapies, and also as an add-on for wet AMD (nAMD). Phase 2a GA data are around the corner (1H21) and the co has a ‘deep bench’ of candidates."

For an analyst ratings summary and ratings history on Gemini Therapeutics Inc. click here. For more ratings news on Gemini Therapeutics Inc. click here.

Shares of Gemini Therapeutics Inc. closed at $16.01 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co